NCT02881268已完成不适用
Study of Immunosuppression Biomarkers Acquired in Patients Hospitalized in Intensive Care Unit
Rennes University Hospital1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2016年1月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- Detection of immunosuppression biomarkers in septic and non-septic patients hospitalized in intensive care unit
研究概览
简要总结
Open-label, non-randomized, prospective, single center, observational, translational study
详细描述
The aim of this trial is to study immunosuppression biomarkers in patients hospitalized in intensive care unit in comparison to non-septic patients.
Prevalence of immunosuppression acquired in intensive care unit will be studied and patients most likely to develop nosocomial infection will be early identified
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient older than 18 years old
- •Patient hospitalized in intensive care unit for any reason
- •Patient with infection started less than 5 days before admission
- •Patient with mechanical ventilation or not
- •Patient with arterial catheter for an invasive monitoring of blood pressure
- •Patient informed about the study protocol and approved to participate.
- •Patients hospitalized for a severe bacterial infection (severe sepsis or septic shock)
- •Patient hospitalized for a non-infectious disease
排除标准
- •Pregnancy
- •Advanced immunosuppression defined by proved humoral or cellular impairment by continuous administration of steroids at any dose since more than one month before hospitalization, transplantation, radiotherapy or chemotherapy in the preceding year
- •Initiation of an immunosuppressive therapy as chemotherapy, cyclophosphamide or high dose corticotherapy (>0.5mg/kg/day)
结局指标
主要结局
Detection of immunosuppression biomarkers in septic and non-septic patients hospitalized in intensive care unit
时间窗: Day 14
次要结局
- Association of immunosuppression biomarkers with patients demographic data(Day 14)
- Association of immunosuppression biomarkers with patients clinical data(Day 14)
- Association of immunosuppression biomarkers with occurrence of events reflecting a clinical immunosuppression(Day 14)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisRelapsing-remitting Multiple SclerosisNCT01310166Novartis Pharmaceuticals447
进行中（未招募）
2 期
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaLocally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaLocally Advanced Urethral Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaMetastatic Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Stage IV Renal Pelvis Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Stage IV Urethral Cancer AJCC v8NCT04848519Emory University6
招募中
不适用
Predictive biomarker study of immune checkpoint inhibitors in metastatic head and neck squamous cell carcinomaNeoplasmsKCT0007598ational Cancer Center50
撤回
4 期
Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for HypophosphatasiaHypophosphatasiaNCT06015750Alexion Pharmaceuticals, Inc.8
已完成
不适用
An exploratory biomarker study of immunecheckpoint inhibitors using tumor tissue and peripheral bloodlung cancer, and melanomaJPRN-UMIN000024414Wakayama Medical University120